期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 58, 期 5, 页码 2921-2924出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02482-13
关键词
-
资金
- The Medicines Company (Parsippany, NJ) via the SENTRY Antimicrobial Surveillance Program platform
- The Medicines Company
- Achaogen
- Aires
- American Proficiency Institute (API)
- Anacor
- Astellas
- AstraZeneca
- bioMerieux
- Cempra
- Cerexa
- ContraFect
- Cubist
- Dipexium
- Enanta
- Furiex
- GlaxoSmithKline
- Johnson Johnson
- LegoChem Biosciences, Inc.
- Meiji Seika Kaisha
- Nabriva
- Novartis
- Pfizer
- PPD Therapeutics
- Premier Research Group
- Rempex
- Rib-X Pharmaceuticals
- Seachaid
- Shionogi
- Theravance
- Thermo Fisher
In this study, oritavancin had modal MIC, MIC50, and MIC90 values of 0.03, 0.03, and 0.06 mu g/ml, respectively, against Staphylococcus aureus. Similar results (MIC50/90, 0.03/0.06 mu g/ml) were observed against methicillin-resistant and -susceptible isolates and those demonstrating multidrug-resistant (MDR) and non-MDR phenotypes. When oritavancin (MIC50/90, 0.06/0.12 mg/ml) was tested against S. aureus with elevated MIC values for daptomycin (i.e., 1 to 4 mg/ml) and vancomycin (i.e., 2 mg/ml), it showed MIC results 2-fold higher than those for the more susceptible vancomycin or daptomycin counterparts (MIC50/90, 0.03/0.06 mg/ml), yet it inhibited these isolates at <= 0.25 mg/ml.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据